In the past half century, one of the most exciting frontiers in the life sciences is Dr. Raphael Mechoulam’s discovery of the Endocannabinoid System (ECS). Mechoulam’s compelling discovery about the pervasiveness and impacts of the ECS on human life has created an opportunity for advancing an evidence base and a field of knowledge in this relatively unexplored area. The implications for medical field are unprecedented. The Clinical Endocannabinoid System Consortium (CESC) is a response to the need to develop a deeper understanding of the ECS and apply that knowledge to clinical practice and to contribute to the emerging public health dialogue about the role of Cannabis in healthcare. The unfolding historic events and recent discoveries have lead a group of scientists, medical doctors and other health care providers to form a non-profit organization, CESC, in order to better understand the Endocannabinoid system and how cannabinoids and related molecules interact with the physiological system. The Dosing Project is the flagship program of The CESC, a non- profit organization. The objective of the Dosing Project is to capture information from a large number of patients and determine how they feel with, and respond to, specific doses of cannabis products for medical conditions, such as chronic pain and disordered sleep..